[{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3434

DSSTox_CID_3434
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

DSSTox_CID_3434

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

10 API Suppliers, 8 USDMF, 2 KDMF, 2 NDC API, 3 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

FINISHED DOSAGE FORMULATIONS

10 FDF Dossiers, 7 FDA Orange Book, 1 Canada, 2 South Africa

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 1 DKSH, 1 Gangwal Healthcare, 1 Actylis, 1 Aeon Procare, 1 Finar, 1 Microlex e.U

EXCIPIENTS BY APPLICATIONS

5 Direct Compression, 4 Fillers, Diluents & Binders, 3 Chewable & Orodispersible Aids, 2 Taste Masking, 2 Parenteral, 1 Co-Processed Excipients

MARKET PLACE

2 APIs, 1 EXCIPIENTS

REF. STANDARDS & IMPURITIES

1 USP, 1 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

02

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

03

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

04

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

05

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

06

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

07

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed

08

Hoth Therapeutics

U.S.A

BioProcess International

Not Confirmed